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Differential proteomic analysis of proteins induced by gluco-
corticoids in cultured murine podocytes.
Background. The glomerular podocyte is the kidney cell most
affected during the development of nephrotic syndrome, and
mutations in podocyte proteins are responsible for a variety
of inherited forms of nephrotic syndrome. Although glucocor-
ticoids are a primary treatment for nephrotic syndrome, nei-
ther their target cell nor mechanism of action are known. In
order to describe the proteome of the podocyte, and to identify
podocyte proteins whose expression is altered by glucocorti-
coids, we performed a differential proteomic analysis of control
and dexamethasone-treated cultured murine podocytes.
Methods. Podocyte proteins were separated by two-
dimensional-polyacrylamide gel electrophoresis (PAGE) and
identified by matrix-assisted laser desorption time-of-flight
(MALDI-TOF) mass spectrometry and peptide fingerprinting.
Comparisons of stained two-dimensional-PAGE separations
were used to identify proteins whose expression was altered
by treatment with the glucocorticoid dexamethasone, and these
results were confirmed by quantitative Western blotting.
Results. A total of 106 protein spots yielded MALDI-TOF
results, and 92 were identified by protein fingerprinting. Of
the 88 unique proteins and four protein isoforms identified, six
proteins were found whose expression was altered by dexam-
ethasone. The proteome of cultured murine podocytes is partic-
ularly rich in actin cytoskeletal proteins and proteins involved
in responses to cellular stress. The change in expression of three
proteins [ciliary neurotrophic factor (CNTF), aB-crystallin, and
heat shock protein 27 (hsp27)] was confirmed by quantitative
Western blotting.
Conclusion. Three proteins with known roles in protecting
cells from injury were up-regulated by dexamethasone, demon-
strating that glucocorticoids exert a direct effect on cultured
podocytes resulting in changes in the expression of proteins with
potential relevance to the therapeutic action of glucocorticoids
in diseases such as nephrotic syndrome.
Key words: ciliary neurotrophic factor, heat shock protein, dexametha-
sone, nephrotic syndrome, actin cytoskeleton.
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The glomerular podocyte is increasingly recognized
as a primary determinant of focal segmental glomeru-
lar sclerosis leading to chronic kidney disease [1, 2], and
recent discoveries have highlighted the importance of
podocyte proteins in maintaining the glomerular filtra-
tion barrier in both health and disease [3]. The podocyte
cell body floats in the urinary space of the glomerulus, and
its primary processes extend to the glomerular capillary,
where secondary and tertiary “foot” processes interdig-
itate and attach to the underlying glomerular basement
membrane (GBM). Specialized adherens junctions called
slit diaphragms span the filtration slits between foot pro-
cesses. The slit diaphragms, together with the GBM and
fenestrated endothelium of the glomerular capillary, form
the kidney’s filtration barrier. Because the podocyte is en-
capsulated within the glomerulus and attached through
its extensive network of foot processes to the GBM, iso-
lation of a significant number of podocytes for primary
culture or biochemical analyses is problematic. In order
to overcome this difficulty, a number of researchers have
isolated cell lines from glomerular outgrowths [4–7], in-
cluding a conditionally-immortalized podocyte cell line
expressing a temperature sensitive form of the SV40 T-
antigen was derived from the Immortomouse [8]. These
cells can be differentiated to become nonproliferative,
arborized cells expressing at least a subset of the pro-
teins characteristic of podocytes in vivo [9]. These murine
podocytes, along with a recently-described line of con-
ditionally immortalized podocytes of human origin [7],
represent the best currently available model system for
analysis of the biochemistry of the podocyte.
Nephrotic syndrome is common in adults and is among
the most common kidney diseases in children [10]. During
development of nephrotic syndrome, several morpho-
logic changes occur in glomerular podocytes, including
retraction and effacement of the podocyte foot processes,
formation of occluding junctions with displacement of slit
diaphragms, and, in severe cases or specific areas, detach-
ment of the podocyte from the GBM [11–15]. Foot pro-
cess effacement correlates closely with the development
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of proteinuria [12, 14, 16], and is the characteristic ultra-
structural finding for nephrotic syndrome.
The most commonly used treatment for nephrotic syn-
drome is oral glucocorticoids, although despite their fre-
quent use, neither the target cell nor the mechanism of
action of glucocorticoids in inducing remission in patients
with nephrotic syndrome has been identified. Due to the
absence of inflammatory cells in the glomeruli of patients
with typical idiopathic nephrotic syndrome [17], soluble
factors, presumably secreted by circulating lymphocytes
[18, 19], have long been implicated as causative agents in
this disease. Although extensively studied for more than
25 years, no consistent abnormalities in either secreted
cytokines, or in the number of total or subsets of T lym-
phocytes, have been identified to date (reviewed in [20]).
The known anti-inflammatory and immunosuppressive
activities of glucocorticoids have historically been taken
as indirect evidence suggesting that their mechanism of
action in nephrotic syndrome involves inhibition of re-
lease of soluble mediators by T lymphocytes [21]. Re-
cently, however, glomerular podocytes have been shown
to contain the glucocorticoid receptor, and the receptor
has been shown to translocate to the nucleus of podocytes
upon dexamethasone treatment [22], demonstrating that
podocytes are capable of responding to glucocorticoids.
We have recently discovered that treatment of cultured
podocytes with dexamethasone both protects from and
ameliorates injury caused by puromycin aminonucleo-
side (PAN), a compound used to induce experimental
nephrotic syndrome in animals. In addition, dexametha-
sone enhances the stability of actin filaments against sub-
sequent disruption by cytochalasin D or latrunculin A
[23]. These findings provide strong evidence suggesting
that glucocorticoids may in fact exert at least part of
their therapeutic action in nephrotic syndrome by act-
ing directly on podocytes rather than via their effects on
lymphocytes.
Proteomic analyses are an increasingly common tech-
nique for characterizing the proteins expressed in normal
organs, tissues, and cells, and for examining the coordi-
nated changes of proteins in response to various stimuli.
Proteomic analyses permit the identification of a large
number of proteins expressed by a particular cell or tissue,
typically by separation of proteins by two-dimensional
polyacrylamide gel electrophoresis (PAGE) or microcap-
illary liquid chromatography, followed by identification
using mass spectrometry. This analysis permits charac-
terization of protein modifications and of translational
regulation that is not available through genomic measure-
ments of changes in mRNA expression. We hypothesized
that a proteomic analysis of cultured murine podocytes
would reveal important clues concerning the nature of
these unique cells, and that a differential proteomic anal-
ysis of the proteins altered by dexamethasone treatment
would identify proteins that may be responsible for the
observed protective and ameliorative effects of dexam-
ethasone in podocytes. The present study was performed
to create a proteome map of the proteins expressed in
differentiated cultured murine podocytes [8], and to dis-
cover and identify proteins whose expression in these
cells is altered by dexamethasone 3 days after treatment,
a time point when podocyte actin filaments were most
resistant to disruption by cytochalasin D and latrunculin
A [23].
METHODS
Cell culture
Murine podocytes derived from the Immortomouse
[8] were cultured and differentiated as previously de-
scribed [24]. Briefly, cells of passage number ≤10 were
grown in RPMI 1640 medium containing penicillin and
streptomycin antibiotics, 10% fetal bovine serum (FBS)
(Gibco Invitrogen, Carlsbad, CA, USA), and 10 U/mL
of interferon-c (INF-c) at 33◦C, and differentiated in the
same medium without INF-c at 37◦C (Sigma Chemical
Co., St. Louis, MO, USA). Cells used in these studies
were seeded at 3.0 × 105 cells per 75 cm2 culture flask or
3.0 × 104 per well of a 6-well tissue culture plate (Greiner
Bio-One, Longwood, FL, USA) and differentiated for
10 to 14 days with medium changes every 4 to 5 days.
Medium was changed 12 hours prior to dexamethasone
treatment. Treatment consisted of a medium change to
medium containing vehicle or 1 lmol/L water-soluble
dexamethasone (Sigma Chemical Co.), followed 30 min-
utes later by another change to medium alone. Treated
cells were cultured for a further 12 hours to 7 days, and
for proteomic analysis were collected 3 days after dexam-
ethasone treatment by brief trypsin digestion followed by
centrifugation at 1000 × g for 3 minutes, and were then
washed once with warm phosphate-buffered saline (PBS)
and recentrifuged.
Phase contrast and fluorescence microscopy
Cultured podocytes differentiated on glass coverslips
were washed in warm PBS, fixed in 3.7% paraformalde-
hyde (Electron Microscopy Sciences, Hatfield, PA, USA)
in PBS for 20 minutes, and lysed by addition of an equal
volume of 0.25% Triton X-100 (Electron Microscopy
Sciences) in PBS and incubation for a further 5 min-
utes. Lysed podocytes were incubated for 20 minutes in
0.05% Tween-20 in PBS (T-PBS) containing 66 nmol/L
Oregon Green 488TM phalloidin (Molecular Probes, Eu-
gene, OR, USA) for phase contrast and phalloidin fluo-
rescence microscopy. In order to visualize synaptopodin,
lysed podocytes were incubated for 1 hour in 5% heat-
denatured horse serum in T-PBS to block nonspecific
protein binding sites, labeled with antisynaptopodin anti-
body (mouse monoclonal antisynaptopodin clone G1D4)
(Research Diagnostics, Flanders, NJ, USA) diluted 1:2
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in 5% horse serum in T-PBS for 1 hour, washed thor-
oughly in T-PBS, and incubated for 1 hour with Texas
Red–conjugated goat antimouse antibody (Jackson Im-
muno Research Laboratories, West Grove, PA, USA) di-
luted 1:100 in 5% horse serum in T-PBS. After washing
in T-PBS, all specimens were mounted in Prolong Anti-
FadeTM mounting reagent (Molecular Probes) and mi-
crographs collected using OpenLab software (Improvi-
sion, Lexington, MA, USA) controlling a Retiga 1300
120-bit grayscale charged coupling device (CCD) cam-
era (QImaging, Burnaby BC, Canada) collecting images
from a Leica DM IRE2 fluorescence microscope (Leica
Microsystems, Bannockburn, IL, USA).
Western blotting
Podocytes were cultured in 6-well plates and treated
(N = 4 samples/treatment) for various times with ei-
ther dexamethasone or vehicle alone. They were washed
with warm PBS and proteins were extracted into 150 lL
of sodium dodecyl sulfate (SDS)-PAGE sample buffer
(62.5 mmol/L Tris-Cl, pH 6.8, 10% glycerol, and 2% SDS)
with gentle rocking for 10 minutes at room tempera-
ture. Extracts were collected, centrifuged at 10,000 × g
for 15 minutes, and an aliquot removed for protein as-
say by BCA microassay (Pierce, Rockford, IL, USA).
2-Mercaptoethanol containing 0.2% bromophenol blue
was added to samples to a final concentration of 5%,
and samples were heated to 100◦C for 4 minutes and re-
centrifuged. Aliquots of sample supernatants containing
30 lg of total protein, and serial dilutions of standard
proteins [aB-crystallin and murine heat shock protein
27 (hsp27) (Stressgen, Victoria, BC, Canada) and cil-
iary neurotrophic factor (CNTF) (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA)] dissolved in sample
buffer were loaded onto 12% discontinuous polyacry-
lamide gels, separated by electrophoresis, and transferred
to polyvinlydine difluoride (PVDF) membranes by im-
mersion blotting. Membranes were washed in PBS con-
taining PBS-T, nonspecific protein binding sites were
blocked by incubation for 1 hour in 5% nonfat dry milk
(Bio-Rad, Hercules, CA, USA) in PBS-T, washed three
times in PBS-T, and incubated for 2 hours in primary anti-
body solutions made in 5% bovine serum albumin (BSA)
(Fraction V) (Sigma Chemical Co.) in PBS-T. Antibod-
ies specific for murine hsp27 and aB-crystallin (Stress-
gen) were used at 1:5000 dilution, for CNTF (Santa
Cruz Biotechnology) at 1:2000 dilution, and for an-
nexin V (Santa Cruz Biotechnology) at 1:1000 dilution.
After three washes, membranes were incubated with
horseradish peroxidase-conjugated antirabbit or mouse
IgG secondary antibodies (Jackson Immunochemicals,
West Grove, PA, USA) diluted 1:10,000 in 5% nonfat
dry milk in PBS-T for 1 hour. Membranes were washed
again, and antibody binding was visualized using an en-
hanced chemiluminescence reagent (SuperSignal West
Pico substrate) (Pierce) as detected by a CCD camera
imaging system (ChemiDoc) (Bio-Rad). The integrated
signal density from antibody staining in digital images of
Western blots was measured using Quantity One soft-
ware (Bio-Rad). Amounts of aB-crystallin, hsp27, and
CNTF proteins were derived from the linear portion of
standard curves of the integrated density of standard pro-
tein signals vs. the quantity of standard protein loaded.
Percent of control values described in the text are the
percentage of the average amount of each specific pro-
tein in dexamethasone-treated samples compared to the
average amount of that protein in time-matched controls.
Sample preparation for two-dimensional-PAGE
Cell pellets from 75 cm2 flasks were suspended in sam-
ple buffer consisting of 7 mol/L urea, 2 mil/L thiourea
(Fisher, Fair Lawn, NJ, USA), 60 mmol/L dithiotreitol
(DTT), 4% CHAPS (Sigma Chemical Co.), and 1.8%
(solids) 3/10 ampholytes (Bio-Rad). Suspensions were
agitated on a vortex mixer for 1 hour and centrifuged
at 16,000 × g for 10 minutes, and quantities of the su-
pernatant containing equal amounts of total protein were
loaded onto the first-dimension isoelectric focusing (IEF)
gel for proteomic analysis. The protein concentration in
supernatants was measured by spectrophotometry us-
ing HP 8453 ultraviolet-visible system (Hewlett-Packard
Company, Palo Alto, CA, USA) and Bio-Rad RCDC
Protein Assay (Bio-Rad).
First dimension of two-dimensional PAGE
An immobilized pH gradient (IPG) IEF gel (pH 3 to
10) (Genomic Solutions Inc., Ann Arbor, MI, USA) was
used for first-dimensional isoelectric focusing using 100
mmol/L sodium hydroxide as the cathode buffer, and 10
mmol/L phosphoric acid as the anode buffer. The protein
samples (100 lg total protein) were loaded onto the IEF
gels with the rehydration buffer and were focused for 17
hours and 30 minutes to reach 18000 volt-hours.
Second dimension of two-dimensional PAGE
The IPG first-dimension strips were incubated in pre-
mixed Tris/acetate equilibration buffer with 0.01% bro-
mophenol blue and 50 mmol/L DTT for 2 minutes before
loading onto precast 10% homogeneous, 22 × 22 cm,
slab gels (Genomic Solutions). Upper running buffer
consisted of 0.2 mol/L Tris base, 0.2 mol/L tricine, and
0.4% SDS and lower running buffer was 0.625 mol/L
Tris/acetate. The system was run with maximum of
500 volts and 20,000 milliwatts per gel.
SYPRO RubyTM staining and visualization
The slab gels were fixed in 10% methanol and 7% acetic
acid for 30 minutes. The fixation solution was removed
and gels were incubated in 500 mL of SYPRO RubyTM
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Fig. 1. Phase contrast and fluorescence micrographs of differentiated podocytes labeled to visualize filamentous actin and synaptopodin. Cultured
podocytes were induced to differentiate, fixed, viewed by phase contrast microscopy (A), or labeled with either Oregon Green 488TM phalloidin
(B) or antisynaptopodin antibody and an appropriate Texas Red-conjugated secondary antibody (C) and viewed under fluorescence illumination.
The micrographs in (A and B) are of the same field (white bar at lower right = 40 lm).
gel stain (Bio-Rad) with gentle, continuous rocking
for 18 hours at room temperature. A high-resolution 12-
bit camera with ultraviolet light box system (Genomic
Solutions) was used to visualize the gel images. Gels
were exposed to ultraviolet light for an optimal time of
3 seconds.
Quantitative analysis of protein expression
Investigator HT analyzer (Genomic Solutions) soft-
ware was used for matching and analysis of the spots on
the gels. Individual spots were matched across gels ini-
tially using automated spot recognition algorithms and
then were confirmed by hand. Spot intensities were first
normalized to total gel fluorescence as an initial adjust-
ment for intergel background variability. A separate anal-
ysis of each spot’s fluorescence intensity was then per-
formed in each gel with additional correction for local
background variability. The average gel was constructed
as a represented gel for each experimental group (N =
7 in each group). Average mode of background subtrac-
tion was used to normalize the intensity volume that rep-
resents the amount of protein per spot. The average gel
was then used for determination of the presence of and
difference of protein expression between each group.
In-gel tryptic digestion, matrix-assisted laser desorption
time-of-flight (MALDI-TOF) mass spectrometry, and
peptide mass fingerprinting
In-gel tryptic digestion and MALDI-TOF mass spec-
trometry were performed using techniques described pre-
viously [25]. Protein identification of peptide fragments
was performed by using the “Profound” search engine
(http://129.85.19.192/profound bin/WebProFound.exe)
based on the entire NCBI protein database using the
assumption that peptides are monoisotopic, oxidized
at methionine residues, and carboxamidomethylated at
cysteine residues. Up to one missed trypsin cleavage
was allowed, although most matches did not contain any
missed cleavages. Mass tolerance of 150 ppm was the
window of error allowed for matching the peptide mass
values. Z scores were estimated by comparison of search
results against estimated random match population
and were the distances to the population mean in units
of standard deviation. Scores greater than 1.65 were
considered statistically significant (P < 0.05). Identities
of protein spots that did not reach this significant level
were not reported.
Statistical analyses
Both unpaired Student t test and the exact mode of the
Mann-Whitney test (SigmaPlot) (SPSS, Inc., Chicago, IL,
USA) were used for comparisons of the differences be-
tween two groups (N = 7 for each group) of staining
intensities in analyses of two-dimensional-PAGE separa-
tions. P values less than 0.05 were considered statistically
significant. This significance level is based on the exact
distribution of a test statistic that is more accurate than
using asymptotic significance values when the sample size
is small. Only the significances that were in agreement be-
tween the Student t test and the Mann-Whitney test were
reported. Data are reported as mean ± SEM.
The unpaired Student t test was used for comparison
of protein quantities derived from standard curves of lu-
minescence intensities on Western blots. Data were re-
ported as mean ± SEM, with P values < 0.05 considered
significant.
RESULTS
Cultured podocyte morphology
and synaptopodin labeling
The cultured podocyte used in this study displayed
an arborized morphology with long, well-developed
cell processes (Fig. 1A) containing actin filaments (Fig.
1B). These cells also stained for synapotopodin in a
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filamentous pattern characteristic of this podocyte-
specific actin-associated protein (Fig. 1C).
Proteomic analysis of cultured podocytes
Protein spots were isolated from two-dimensional-
PAGE separations of extracts of differentiated, cultured
murine podocytes and subjected to MALDI-TOF mass
spectrometry and protein fingerprinting. Of 106 pro-
tein spots yielding MALDI-TOF results, 92 were iden-
tified by a search of the NCBI protein database using
the Profound search engine. Of the identified proteins
(Table 1), 88 were unique proteins and four were pro-
tein isoforms of one of the identified proteins (moesin,
nonmuscle caldesmon, vimentin, and heterogeneous nu-
clear riboprotein K). Identified proteins were of the
expected pI and molecular weight in two-dimensional-
PAGE separations.
The proteins identified in cultured podocytes were or-
ganized into categories (Table 1) based on functional
information in their PubMed and SwissProt protein
database entries and on other published reports. As ex-
pected, a number of metabolic enzymes and enzymes
involved in amino acid synthesis and other basic cellu-
lar functions were identified. Podocytes also expressed
several members of classes of proteins important for re-
sponse to cellular stress, including antioxidant enzymes,
heat shock proteins, and chaperonins. Members of several
classes of cell signaling proteins, including phosphatases,
guanosine diphosphate (GDP) dissociation inhibitors,
transcription factors, and the 14–3-3 zeta scaffolding pro-
tein were identified. The largest class of proteins found
in podocytes was cytoskeletal proteins, and, in particular,
actin cytoskeletal proteins and proteins primarily known
for their association with the actin cytoskeleton. Several
classes of proteins were also found and grouped by their
association with subcellular organelles such as the endo-
plasmic reticulum, mitochondria, and the plasma mem-
brane (e.g., annexins). Finally, several proteosome pro-
teins, serine protease inhibitors, an intracellular chloride
channel, and a protein previously described as a neuronal
cytokine (CNTF) were identified.
Comparative proteomic analysis of
dexamethasone-treated podocytes
Proteins were extracted from cultured murine
podocytes 3 days after a 30-minute treatment of seven
cultures each with vehicle or with 1 lmol/L dex-
amethasone, and extracted proteins were separated
by two-dimensional-PAGE. The results of analyses of
stained two-dimensional-PAGE separations (represen-
tative stained separations of extracts from vehicle and
dexamethasone-treated podocytes are shown in Fig. 2)
were used to determine differences in protein expression
between vehicle- and dexamethasone-treated podocytes.
These analyses revealed six proteins whose expres-
sion was significantly altered 3 days after dexametha-
sone treatment when compared with extracts from cells
treated with vehicle alone (Table 2). The expression of
five of these proteins (purine nucleotide phosphorylase,
annexin 5, CNTF, aB-crystallin, and gelsolin) was signifi-
cantly increased by dexamethasone, and only the expres-
sion of the lysosomal adenosine triphosphatase (ATPase)
proton pump was significantly reduced after dexametha-
sone treatment.
Confirmation of proteomic results by quantitative
Western blotting
The increases in the amounts of CNTF and aB-
crystallin proteins at 3 days observed in our proteomic
analysis were confirmed by a Western blot analysis us-
ing appropriate antibodies against these proteins. The
magnitudes of the increases in CNTF and aB-crystallin
protein 3 days after dexamethasone treatment derived
from measurements of chemiluminescence compared to
standard proteins (250% and 301% of time-matched con-
trols, respectively) were greater than the values obtained
by comparison of stained gels in the proteomic analyses
(197% and 165% of time-matched controls, respectively).
In addition, the amount of CNTF and aB-crystallin was
higher in dexamethasone-treated podocytes than in time-
matched controls as early as 1 day after dexametha-
sone treatment and remained elevated for at least 7 days
(Fig. 3). The largest amount of these proteins was found
in podocytes at 7 days after dexamethasone treatment,
with 14.5 ± 1.5 ng of CNTF per 1000 cells (277% of
time-matched controls) and 1.27 ± 0.1 ng of aB-crystallin
per 1000 cells (463% of time-matched controls). We also
noted increases in the amount of hsp27 (Fig. 3), a small
heat shock protein closely related to aB-crystallin, that
were comparable in magnitude (425% of time-matched
controls at 1 day after dexamethasone treatment) but
reached maximal levels earlier (1 day after treatment)
than dexamethasone-induced increases in aB-crystallin
expression. We were unable to reproducibly confirm
changes in the amount of annexin 5 induced by dexam-
ethasone by quantitative Western blotting. We did not
measure changes in the amounts of purine nucleoside
phosphorylase, lysosomal ATPase, or gelsolin in extracts
of podocytes.
DISCUSSION
This study was designed to identify proteins of the
proteome of cultured differentiated murine podocytes,
and to discover and identify podocyte proteins whose ex-
pression was altered by a glucocorticoid treatment previ-
ously shown to protect these cells from injury and direct
cytoskeletal disruption. We successfully identified a to-
tal of 92 protein spots representing 88 unique proteins,
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Table 1. Proteins identified in cultured murine podocytes by proteomic analysis
Protein Spot number GI number Molecular weight pI
Metabolic enzymes
Aldolase 1, alpha isoform 88 6671539 39800 8.31
Enolase 1, alpha non-neuron 65 13637776 47500 6.37
Lactate dehydrogenase 57 65923 36800 7.62
Lactate dehydrogenase 2, B chain 4 6678674 36834 5.7
Malate dehydrogenase, soluble 19 31982178 36600 6.16
3-Phosphoglycerate dehydrogenase 29 13928850 57200 6.28
Phosphoglycerate kinase 87 129903 44900 8.0
Phosphoglycerate mutase type B subunit 6 8248819 28930 6.7
Pyruvate kinase 3; M2 isozyme 16 1363219 58400 7.58
Transketolase 84 12018252 71940 7.54
Antioxidant enzymes
Cu/Zn-superoxide dismutase 89 201006 16100 6.23
Glutathione-S-transferase, mu 1 77a 6754084 26100 7.71
Peroxiredoxin 1 80 547923 22500 8.26
Peroxiredoxin 2 (type II peroxiredoxin-1) 34 3603241 22000 5.2
Peroxiredoxin 6 (1-Cys peroxiredoxin protein) 39 4139186 25000 5.98
Other enzymes
Aldose reductase 58 1351911 34700 7.04
ATPase, lysosomal H+ transport, subunit D, isoform 2 100 31981304 56900 5.6
Cytosolic nonspecific dipeptidase 17 31981273 53162 5.43
Esterase 10, D 20 13937355 37800 6.7
Glucose-regulated protein, 58 kD (phospholipase C, alpha) 13 20911547 57099 5.88
Glutamate dehydrogenase 28 6680027 61700 8.05
Ornithine aminotransferase 61 8393866 48700 6.19
Peptidylprolyl isomerase A; cyclophilin A 43 6679439 18131 7.74
Purine-nucleoside phopshorylase 10 7305395 32527 5.78
Thioether S-methyltransferase 5 6678281 30068 6
Ubiquinol-cytochrome c reductase core protein 1 95 13384794 53400 5.8
UMP-CMP kinase (cytidylate kinase) 91 23821758 22400 5.68
Phosphatases
Protein phosphatase 1 alpha 97 13994195 38300 5.9
Protein phosphatase 1 delta 98 227436 38000 5.8
Phosphoprotein phosphatase 66 1663530 54700 6.23
GDP dissociation inhibitors
Rab GDP dissociation inhibitor alpha 102 21903424 51000 4.96
GDP dissociation inhibitor 3 9 6679987 51000 5.93
Rho GDP dissociation inhibitor 1 2 31982030 23464 5.12
Nuclear proteins
Par-4 (PRKC, apoptosis response protein) 30 20865316 36000 5.74
Heterogeneous nuclear ribonucleoprotein K 69, 70 13384620 51300 5.19
Bat1 nuclear RNA helicase 96 19773876 49400 5.43
Other regulatory proteins
14–3-3 Zeta protein 82 7435027 27900 4.72
Actin cytoskeletal and binding proteins
Actin-related protein (Arp) 3 8 12835802 47743 5.54
Ezrin (villin 2) 93 32363497 69500 5.9
F-actin capping protein alpha-1 subunit 103 1345694 33000 5.34
F-actin capping protein alpha-2 subunit 106 6671672 33500 5.57
F-actin capping protein beta-subunit (Cap Z) 36 34223730 31000 5.5
Nonmuscle caldesmon 45, 46 2498205 65000 6.34
Gelsolin 94 18606238 81000 5.5
LIM and SH3 protein 1 (Lasp-1) 41 6754508 30300 6.61
Moesin 27 13540689 68000 6.2
Moesin 92 462608 67800 6.22
Myosin regulatory light chain 2-a, smooth muscle isoform 52 127170 19900 4.78
Septin 6 15 20178348 50000 6.36
Transgelin 2 81 9910901 22500 8.39
Tropomyosin, alpha isoform, nonmuscle 51 207351 32700 4.76
Tropomyosin, alpha isoform 33 14134104 32773 4.7
Tropomyosin 4 23 6981672 28564 4.66
Tropomyosin 5 83 111212 29200 4.75
Vimentin 49, 50 2078001 53700 4.96
Other cytoskeletal proteins
Laminin receptor 1 31 31560560 33000 4.8
Tubulin alpha 1 25 33440506 50100 4.94
Calcium-dependent protease, small subunit 35 18202239 28500 5.41
Translationally controlled tumor protein 1 44 6678437 19600 4.8
Collapsing response mediator protein 2 (CRMP-2) 14 40254595 62531 5.95
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Table 1. (Continued).
Protein Spot number GI number Molecular weight pI
Annexins
Annexin I 11 6754570 38952 6.56
Annexin II 7 6996913 39000 7.55
Annexin III 3 7304887 36533 5.33
Annexin IV 21 2492905 36200 5.43
Annexin V 24 6753060 35787 4.83
Annexin VII 60 584761 50200 5.91
Heat shock proteins
Alpha B-crystallin 42 6753530 20000 6.76
Hsp8, Hsp cognate 70 1 31981690 71021 5.37
Hsp60 protein 12 1334284 58061 5.35
Stress-70 protein, mitochondrial precursor (Mortalin) 67 1346171 74000 5.72
Chaperonins
T complex polypeptide (TCP) 1 72 201725 60000 5.82
TCP-1 beta subunit 63 5295927 57800 5.97
TCP-1 theta subunit 71 1174621 60000 5.44
Chaperonin subunit 5 (epsilon) 47 6671702 60000 5.7
Proteosome proteins/protease inhibitors
Proteasome 28 subunit, alpha 37 6755212 28800 5.73
Proteasome subunit, alpha type 1 38 9910833 29800 6
Proteasome subunit, beta type, 4 90 3914439 29200 5.47
Serine protease inhibitor 3 105 6678097 42900 5.53
Phosphatidylethanolamine binding protein 54 9256572 21000 5.2
Endoplasmic reticulum proteins
Protein disulfide isomerase precursor (PDI) 68 129729 57500 4.79
Calreticulin 32 6680836 48100 4.33
78 kD glucose-related protein precursor (GRP78, Bip) 101 2506545 72500 5.07
Protein disulfide isomerase A3 precursor (GRP58, HIP-70) 104 1352384 57000 5.9
Mitochondrial proteins
Chlorine intracellular channel 4, mitochondrial (mtCLIC/CLIC4) 55 7304963 29000 5.44
ATP synthase, H+ transporting, mitochondrial F1 complex 85 6680748 59800 9.2
Prohibitin 56 6679299 29800 5.57
Other proteins
Chloride intracellular channel 1 22a 15617203 27338 5.09
Ciliary neurotrophic factor (CNTF) 40 16507247 22600 6.05
GI, GenInfo identifier; pI, isoelectric pH value.
and determined that the expression of six of these pro-
teins was altered by treatment with dexamethasone. In
addition to identifying two glucocorticoid-up-regulated
proteins with known roles in cell survival (CNTF and
aB-crystallin), a third up-regulated protein (hsp27) was
identified by Western blotting due to its high homology
to aB-crystallin.
We present for the first time, to our knowledge, a
proteomic analysis of a glomerular cell type (podocyte),
and a differential analysis of changes in protein expres-
sion in any cell type in response to glucocorticoids. A
limited number of renal proteomic analyses have been
performed to date, including proteomic profiles of urine
proteins [26–29], renal cancer cells [30, 31], isolated prox-
imal tubules [32], and kidney tissue [29, 33]. The only
analysis we are aware of on the effect of steroids on the
mammalian proteome is a study describing a genomic and
proteomic analysis of prostate cancer cells in response to
dihydroxytestosterone [34].
The proteome of differentiated, cultured murine
podocytes is particularly rich in actin cytoskeletal pro-
teins, annexins, and stress-associated proteins such as
heat shock proteins and antioxidant enzymes (Table 1).
Only a limited subset of the proteins identified in cultured
podocytes were also found in other proteomic analyses
of the kidney, the majority of overlap consisting of cy-
toskeletal proteins [35, 36], as well as hsp60, aB-crystallin,
and chloride intracellular channel 1 [33]. The commonal-
ity of cytoskeletal proteins between podocytes and kidney
proteomes may simply be a function of their ubiquitous
expression and relatively high abundance in eukaryotic
cells. It is, however, difficult to draw any conclusions from
the relative paucity of proteins common to the podocyte
proteome described in this analysis and other currently
available kidney proteomes analyses, primarily because
the published renal proteomes consist only of proteins
differentially expressed in response to some stimulus [36]
or common in both cortical and medullary tissues [33, 37].
Proteomic analyses of renal cell carcinomas [30, 31], cul-
tured fibroblasts [38], umbilical vein endothelial cells [39],
and, in particular, cultured, differentiated mammary cells
[40] contained a larger and more diverse subset of pro-
teins in common with cultured, differentiated podocytes.
The greater overlap between known proteomes of cul-
tured cells than between cultured podocytes and whole
kidney is not particularly noteworthy, particularly since
the analyses of renal tissues were restricted to a small
subset of identified proteins. The major species present in
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A
B
Fig. 2. Representative SYPRO RubyTM stained two-dimensional-
polyacrylamide gel elctrophoresis (PAGE) separations of proteins from
dexamethasone- or vehicle-treated cultured podocytes. Protein extracts
from podocytes treated for 30 minutes with vehicle alone (A) or with
1 lmol/L dexamethasone (B) and cultured in fresh medium for 3
days were separated by two-dimensional-PAGE and the resulting gels
stained with SYPRO RubyTM. Positions of protein spots identified
by matrix-assisted laser desorption time-of-flight (MALDI-TOF) mass
spectroscopy and peptide fingerprinting are shown (A), and positions of
proteins differentially regulated by dexamethasone are indicated sepa-
rately (B).
common in cultured cell proteomes were members of the
annexin family, heat shock proteins, and actin cytoskele-
tal proteins.
We identified six proteins whose expression was altered
by dexamethasone treatment. Of these proteins, the lyso-
somal ATP-driven proton pump was the only protein sig-
nificantly decreased by dexamethasone-treatment. The
lysosomal proton pump is responsible for maintaining
the acidic conditions required for activity of hydrolytic
enzymes present in this organelle, and is a member of
a large family of proteins responsible for proton trans-
port across a number of eukaryotic membranes. A re-
cent study in cultured podocytes (in a different line than
those used in the current study) has shown that inter-
leukin (IL)-4 and IL-13, lymphocytic cytokines that may
be implicated in induction of nephrotic syndrome, can
stimulate proton flux across the basolateral membrane
of these cells, presumably by increasing the basolateral
fusion of lysosomal or endosomal vesicles [41]. This pro-
cess may lead to changes in intracellular trafficking and
to increased proteolytic activity at the basolateral mem-
brane of podocytes, suggesting that the lysosomal ATPase
(or another proton pump) may play a role in the devel-
opment of changes in podocyte foot process morphology
characteristic of nephrotic syndrome by enhancing the
degradation of transmembrane receptors in podocytes or
extracellular matrix proteins. Furthermore, our observed
down-regulation of this enzyme in cultured podocytes in
response to dexamethasone suggests the hypothesis that
down-regulation of lysosomal ATPase may act to protect
the podocyte from injury.
The amount of three proteins, the IL-6–type cytokine,
CNTF, and two small heat shock proteins, aB-crystallin
and hsp27, increased significantly in podocytes 3 days
after dexamethasone treatment as determined by West-
ern blotting. CNTF was first isolated as a factor neces-
sary for the survival of chick embryo ciliary ganglionic
neurons [42], and has subsequently been shown to en-
hance survival and protect a variety of different cells
from injury [43]. CNTF is found in a variety of tissues,
and high expression levels have been measured in the
kidney [44]. Both aB-crystallin and the closely related
hsp27 are widely expressed proteins that may interact
with both actin and intermediate filaments [45–48], act
as molecular chaperones [49, 50], and can induce ther-
motolerance [51, 52]. aB-crystallin has previously been
shown to be induced in NIH-3T3 cells by treatment with
dexamethasone, and the increase in aB-crystallin corre-
lated with an increase in thermoprotection [53]. The time
course of enhanced aB-crystallin expression after treat-
ment in this study was similar to the results we observed
in cultured podocytes. In a separate study, comparative
two-dimensional-PAGE revealed that aB-crystallin was
the protein whose expression was most altered by dexam-
ethasone in NIH-3T3 cells [54]. However, the expression
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Table 2. Proteins altered by dexamethasone
Protein Density (control) Density (dexamethasone) % Changea P value
ATPase, H+ transport, lysosomal 25355 ± 6831 18322 ± 4066 −72 0.030
Annexin 5 128013 ± 47339 192253 ± 37242 150 0.026
Ciliary neurotrophic factor 31776 ± 9584 62590 ± 9762 197 0.000
aB-Crystallin 51925 ± 17872 85423 ± 23515 165 0.020
Gelsolin 47927 ± 26249 79477 ± 34044 166 0.062
Purine nucleotide phosphorylase 30662 ± 5984 65267 ± 8235 213 0.000
aPercentage change in mean dexamethasone density compared to mean control density (N = 7); mean normalized density ± SD.
CNTF
αB-Cry
Hsp27
0 0.5 1 3 5 7
Days after DEX
Fig. 3. Representative Western blots of protein extracts of podocytes at
various times after dexamethasone treatment. Proteins were extracted
from podocytes at 0, 0.5, 1, 3, 5, or 7 days after treatment for 30 minutes
with 1 lmol/L dexamethasone and subjected to Western blotting using
antibodies against ciliary neurotophic factor (CNTF), aB-crystallin, or
heat shock protein 27 (hsp27) as indicated at left. After application
of secondary antibodies and chemiluminescent visualization, determi-
nation of absolute amounts of protein were made by comparison of
luminescence intensities to those of serial dilutions of specific standard
proteins separated in the same gels, and comparisons were made to
time-matched control values (see text for results).
of hsp27 was not shown to be altered by dexamethasone
in NIH-3T3 cells [53], though in rat cerebellar slices given
a mild heat shock after treatment with the glucocorticoid
corticosterone, hsp27 was induced compared to tissue re-
ceiving heat shock alone [55], the expression of hsp27
was induced by dexamethasone in osteoblasts [56] and
mouse skin [57], and the expression of both hsp27 and aB-
crystallin were induced by dexamethasone in muscle cells
[58]. Recent studies have suggested protective or amelio-
rative roles for these proteins in the kidney, describing
enhanced expression of CNTF and CNTFRa in injured
kidney tissues following ischemia/reperfusion injury [59],
and that the expression of hsp27 is directly related to the
resistance of cultured podocytes to the morphologic and
actin cytoskeletal injury caused by the podocyte toxin,
PAN [24].
The amounts of gelsolin, annexin V, and purine nucle-
oside phosphorylase increased significantly in podocytes
3 days after dexamethasone treatment as determined
by comparisons of two-dimensional-PAGE separations.
Gelsolin is the most potent known actin filament-severing
protein, and the only known calcium-dependent actin-
severing protein. Gelsolin has only been detected in
the podocyte during fetal development [60]. A gelsolin
mutation resulting in a single aspartate to asparagine
substitution at amino acid 187 results in Finnish-type fa-
milial amyloidosis with severe neural effects [61], but in-
dividuals with homozygous mutations at this locus also
suffer severe renal disease [62]. These results, coupled
with the increasing body of evidence linking proteins
critical to podocyte function to the actin cytoskeleton
[63–66], suggest that altering gelsolin levels in the tightly
regulated system controlling actin polymerization may
have profound effects on podocyte function. Annexins
are highly conserved calcium-binding proteins, and after
calcium binding annexin V binds with high affinity to an-
ionic phospholipids [67]. Annexin V has been localized
to the podocyte in vivo, and the amount of annexin V ex-
creted in the urine increased with increasing renal injury
in experimental rat glomerulonephritis [68]. However,
the up-regulation of annexin V we discovered in cultured
podocytes in response to dexamethasone may be con-
sequence of their differentiation. Glucocorticoids have
previously been demonstrated to induce differentiation
in a variety of cells in culture [69], and proteomic analy-
ses of cultured cells have found annexin V in quiescent
cultures of primary human umbilical vein endothelial
cells, and down-regulated in adaptation of bladder car-
cinoma cells to culture [39, 70]. Purine nucleoside phos-
phorylase catalyzes the phosphorolysis of the N-ribosidic
bonds of purine nucleosides and deoxynucleosides, and is
a key enzyme in the purine salvage pathway. A variety of
mutations in the gene encoding purine nucleoside phos-
phorylase result in the rare autosomal-recessive disease,
purine nucleoside phosphorylase deficiency, that results
primarily in neural and T-cell defects [71]. However, no
renal abnormalities were observed in either human pa-
tients with purine nucleoside phosphorylase deficiency
or in purine nucleoside phosphorylase knockout mice,
suggesting that purine nucleoside phosphorylase is not
essential for podocyte function.
CONCLUSION
We have performed an initial analysis of the proteome
of cultured, differentiated podocytes, and have identified
six proteins whose expression is altered in these cells
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by treatment with dexamethasone. The up-regulation
of CNTF and aB-crystallin was confirmed by quantita-
tive Western blotting, and hsp27, a protein closely re-
lated to aB-crystallin, was also found to be upregulated
in podocytes by dexamethasone treatment. All three of
these proteins have previously been shown to protect cells
against cell stress and injury (hsp27 and aB-crystallin) or
to enhance cell survival (CNTF), suggesting that the up-
regulation of one or more of these proteins may account
for the observed protective and ameliorative effects of
dexamethasone treatment against podocyte injury. These
results demonstrate that dexamethasone acts directly on
podocytes leading to increases in the expression of pro-
teins with known protective roles, and suggest potential
mechanisms of action for the therapeutic effect of glu-
cocorticoids in diseases such as nephrotic syndrome that
primarily affect the glomerular podocyte.
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